Cidara Therapeutics, Inc.
CDTX
$220.98
$1.090.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -420.69% | -- | -127.39% | -1,527.98% | -75.52% |
| Total Depreciation and Amortization | -54.10% | -- | -12.50% | 51.28% | 177.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -100.00% |
| Total Other Non-Cash Items | 216.63% | -- | -435.04% | 78.96% | 0.00% |
| Change in Net Operating Assets | 279.90% | -- | 84.91% | 295.59% | -441.73% |
| Cash from Operations | -10.68% | -- | -230.37% | -131.21% | -2,145.72% |
| Capital Expenditure | -- | -- | -- | 100.00% | 15.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -166,381.13% | -- | 904.35% | 100.00% | 15.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | 0.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 1,228,412.50% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 187.91% | -- | 182.80% | 1,227,462.50% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -486.55% | -- | -220.83% | 633.59% | -2,001.31% |